Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.


Make a donation

InfoSessions & Webinars — Thursday, June 17, 2021, 16:00 - 17:00

Myeloma 101: Diagnosis & Treatment

Myeloma 101: Diagnosis & Treatment

Thursday, June 17, 2021
4:00 – 5:00 pm EST

Register Now!

This InfoWebinar will discuss:

  • ​What is myeloma?
  • How is myeloma diagnosed?
  • How is myeloma treated in Canada?
  • How is myeloma monitored for relapse?

Presented by: 
Dr Deepa Wadhwa
Medical Oncologist
BC Cancer – Kelowna (Sindi Ahluwalia Hawkins Centre)
Clinical Assistant Professor
University of British Columbia
Kelowna, BC

Join us online from the comfort of your own home! All you need is a computer, tablet or smart phone and an internet connection. Click here to register for the webinar.